Series
Cardiac electrophysiology
Status
Published
Date
Number of report
050
Cardiac pacemakers
Ask the expert
The report presents a summary of reimbursement situation for cardiac pacemakers.
Both single- and dual-chamber pacemakers are considered. Use of pacemakers is considered in complete atrioventricular block and obstructive hypertrophic cardiomyopathy.
Reimbursement analysis covers the following procedures: implantation, replacement and removal of pacemaker.
The only reimbursement within public / statutory health insurance systems is considered.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- Austria
- Belgium
- Denmark
- England (UK)
- France
- Germany
- Italy
- Netherlands
- Norway
- Sweden
- Switzerland
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of devices for cardiac pacemakers include:
- Abbott Vascular (Assurity MRI, Endurity MRI)
- Biotronik (Enitra, Effecta, Epyra, Estella, Evia, Edora)
- Boston Scientific (Essentio, Accolade, Ingenio, Advantio, Vitalio)
- Qinming Medical (Qinming)
- MicroPort CRM (Kora, Reply, Esprit)
- Medico S.p.A. (Gea, Hera, Eos, Sophos, Helios, Mythos, Easy Plus)
- Medtronic (Azure, Advisa MRI, Adapta, Micra, Revo MRI SureScan, Sensia, Versa, EnRhythm, EnPulse, Sigma, Kappa)
- Pacetronix (Tiranga, Pinnacle, CHARAK, Pinnacle-R)
- Vitatron (Vitatron)
Table of content is not available at the moment. Report is still ongoing.
24
Mar 2022
The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.
Read more11
Mar 2022
On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.
Read more15
Feb 2022
In January 2022, the Basque Office for Health Technology Assessment (OSTEBA) released an HTA report aiming to assess and compare the efficacy, effectiveness, and safety of the mechanical circulatory support devices most used in the healthcare setting for the treatment and prevention of cardiogenic shock, including Impella® devices, intra-aortic balloon pumps, and extracorporeal membrane oxygenation.
Read more14
Feb 2022
On January 28, 2022, the Institute for the Hospital Remuneration System (InEK) has published the list of the requests for innovation funding (NUB) that were submitted by the hospitals in 2021. The medical technologies belonging to the cardiovascular, ENT, eHealth, gastrointestinal, neuromodulation, neurovascular, orthopedic, and other technology groups obtained positive status 1.
Read more26
Jan 2022
On January 14, 2022, the Government of the Russian Federation released a Decree which approved the inclusion of three devices (implantable pulse generator for urinary/fecal incontinence, bioprosthetic aortic valve/xenoprosthesis, and vessels embolization material) in the List of Essential Implantable Medical Devices.
Read more